Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epoprostenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | PPARD | Q03181 | 2/20 | 0.71 |
| ▸ | PPARA | Q07869 | 2/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.71 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.56 |
| ▸ | PTGFR | P43088 | 2/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.56 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epoprostenol SCHEMBL3165288 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL8041 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL22607961 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24340812 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL551617 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24033081 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL6227413 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24612535 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL21283002 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL8042 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099311-A2 | MICROBIAL CELL FACTORIES PRODUCING PROSTAGLANDINS | RIVER STONE BIOTECH APS (DK) | 2026-05-15 | — | — | WO | claimed |
| US-11654162-B2 | Cell-based therapy for the pulmonary system | Northern Therapeutics, Inc. (CA) | 2023-05-23 | — | — | US | claimed |
| US-20170348275-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-12-07 | — | — | US | claimed |
| US-20150164853-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2015-06-18 | — | — | US | claimed |
| EP-4748386-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT | Fibrobiologics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026099311-A2 | MICROBIAL CELL FACTORIES PRODUCING PROSTAGLANDINS | RIVER STONE BIOTECH APS (DK) | 2026-05-15 | — | — | WO | disclosed |
| EP-4257143-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT | FIBROBIOLOGICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250381180-A1 | METHODS OF TREATING OR PREVENTING OVERACTIVE BLADDER SYNDROME | PURDUE PHARMA L.P. (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4543428-A1 | METHODS OF TREATING OR PREVENTING OVERACTIVE BLADDER SYNDROME | Purdue Pharma L.P. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12239823-B2 | Drug mixing and delivery system and method | WINDGAP MEDICAL, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-119421705-A | Methods for treating or preventing overactive bladder syndrome | 普渡制药公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119242523-A | Breast milk-derived bifidobacterium longum YG4059 and application thereof in constipation improvement | 北京禹景药业有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-110218218-B | Benzofuran derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3976032-A1 | CONCURRENT ACTIVATION OF REGENERATIVE AND TOLEROGENIC PROCESSES BY FIBROBLAST-BASED COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Figene, LLC (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20170348275-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-12-07 | — | — | US | disclosed |
| US-9763911-B2 | Prostacyclin compositions for regulation of fracture repair and bone formation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-09-19 | — | — | US | disclosed |
| US-20150164853-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2015-06-18 | — | — | US | disclosed |
| US-20090252685-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PROSTAGLANDINS AND RELATED COMPOUNDS | PREMIER RESEARCH INTERNATIONAL, LLC | 2009-10-08 | — | — | US | disclosed |
| US-20090252685-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PROSTAGLANDINS AND RELATED COMPOUNDS | PREMIER RESEARCH INTERNATIONAL, LLC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164853-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | PTGIR, PTGIS, PTGS1 | PTGIR 1/4885ALDH1A1 3437/4885MEN1 4003/4885 |
| US-20170348275-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | PTGIR, PTGIS, PTGS1 | PTGIR 1/4885ALDH1A1 3437/4885MEN1 4003/4885 |
| US-20250381180-A1 | METHODS OF TREATING OR PREVENTING OVERACTIVE BLADDER SYNDROME | REN, OTC, ACHE | PTGIR 119/4885ALDH1A1 415/4885MEN1 2575/4885 |
| US-20090252685-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PROSTAGLANDINS AND RELATED COMPOUNDS | PTGER1, HPGDS, PTGER2 | PTGIR 6/4885ALDH1A1 2329/4885MEN1 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.